Trademark dilution

Dilutional Receives the 2023 Global Recognition Award(TM)

Retrieved on: 
Wednesday, October 11, 2023
News, NYSE, Trademark dilution, Pulse, Cryptocurrency

New York, New York--(Newsfile Corp. - October 11, 2023) - In a significant achievement, the innovative platform Dilutional and its founder, Alex Näslund, have garnered a 2023 Global Recognition Award.

Key Points: 
  • New York, New York--(Newsfile Corp. - October 11, 2023) - In a significant achievement, the innovative platform Dilutional and its founder, Alex Näslund, have garnered a 2023 Global Recognition Award.
  • The deciding factors for awarding Dilutional the 2023 Global Recognition Award relate to both the platform's unique features and its potential for revolution.
  • The 2023 Global Recognition Award bestowed upon Dilutional is not just an accolade - it's also an affirmation of their business strategy and a bright marker signaling their predicted future success.
  • Commenting on Dilutional's success, Alex Sterling of Global Recognition Awards™ said, "The recognition Dilutional has achieved today testifies its innovation, resilience, and confidently demonstrated potential.

Ermenegildo Zegna Group Completes Acquisition of Tom Ford International and Enters Into a Long-Term License Agreement With The Estée Lauder Companies for TOM FORD FASHION

Retrieved on: 
Friday, April 28, 2023
Other Retail, Online Retail, Manufacturing, Luxury, Department Stores, Fashion, Cosmetics, Retail, Textiles, Home Goods, Footwear, Intellectual property, Trademark dilution, Calendar, Merchandising, FORD, TFI, Acquisition, Collection, ELC, Fleming Companies, Inc, Adjustment, NYSE, Fashion design

Ermenegildo Zegna N.V. (NYSE: ZGN) (“Zegna Group,” the “Group,” “Zegna,” or the “Company”), owner of the ZEGNA™ and Thom Browne™ brands, today announced the completion of its acquisition of Tom Ford International LLC (“TFI”), the company that owns and operates the TOM FORD fashion business (“TOM FORD FASHION”).

Key Points: 
  • Ermenegildo Zegna N.V. (NYSE: ZGN) (“Zegna Group,” the “Group,” “Zegna,” or the “Company”), owner of the ZEGNA™ and Thom Browne™ brands, today announced the completion of its acquisition of Tom Ford International LLC (“TFI”), the company that owns and operates the TOM FORD fashion business (“TOM FORD FASHION”).
  • Before the completion of the acquisition, Zegna Group already owned 15% of TFI, and in this transaction, it acquired the remaining 85%.
  • Zegna Group will be in charge of the end-to-end TOM FORD FASHION business, from collection creation and development to merchandising, through to production, as well as retail and wholesale distribution.
  • For the year ended December 31, 2022, TFI had revenues of €312 million.1
    TOM FORD FASHION, under Zegna Group, will operate a network of approximately 50 directly operated TOM FORD stores globally.

ToughBuilt Industries Inc. Launches New Line of Long-Handle Garden and Landscaping Tools

Retrieved on: 
Monday, December 5, 2022
Creativity, Sawhorse, Work-product doctrine, Consumables, Security (finance), Government, TBLT, Trademark dilution, Risk, Growth, Stock, COVID-19, Renewable energy, Risk management

IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- ToughBuilt Industries, Inc. ("ToughBuilt") (NASDAQ: TBLT; TBLTW), announced today the launch of the Company’s new line of Long Handle Garden and Landscaping Tools.

Key Points: 
  • IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- ToughBuilt Industries, Inc. ("ToughBuilt") (NASDAQ: TBLT; TBLTW), announced today the launch of the Company’s new line of Long Handle Garden and Landscaping Tools.
  • Beginning with 11 out of about 150 SKUs, the new line includes many innovative improvements.
  • In response to rapidly growing demand, ToughBuilt is expanding its product offerings in the garden tools category.
  • Currently, we are focused on tools and other accessories for the professional and do-it-yourself construction industries.

NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Thursday, December 1, 2022
Medical Devices, Health, 3rd Floor, Trademark dilution, Security (finance), Sale, SEC filing, Risk, Research, SAW, Form, Biofilm, Park Avenue, Clinical trial

The gross proceeds from the offering were $2.4 million, before deducting the placement agents fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds from the offering were $2.4 million, before deducting the placement agents fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from the offering for general working capital purposes.
  • The shares of common stock described above were offered and sold by the Company in a registered direct offering pursuant to a shelf registration statement on Form S-3 (File No.
  • The offering was made only by means of a prospectus supplement that forms a part of the effective registration statement.

ToughBuilt Industries Expands Relationships with Additional SKUs Available in Three Major Retailers Across Europe

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Growth, Consumables, Wickes, Sawhorse, United Kingdom, Work-product doctrine, Trademark dilution, Toolstation, Creativity, Government, Stock, Security (finance), TBLT, Risk, Video game, Risk management

After a successful launch of ToughBuilt products, Wickes, which has 230 locations across the United Kingdom, will be increasing the number of ToughBuilt SKUs available to its customer base, from 15 to 48 SKUs beginning January 2023.

Key Points: 
  • After a successful launch of ToughBuilt products, Wickes, which has 230 locations across the United Kingdom, will be increasing the number of ToughBuilt SKUs available to its customer base, from 15 to 48 SKUs beginning January 2023.
  • Toolstation France has also more than doubled its original offering of the ToughBuilt range to from 25 to 65 SKUs in total.
  • Michael Panosian, ToughBuilt CEO-Founder, stated, We are pleased to extend our relationship with these three recognized European retailers, and that ToughBuilt continues to rapidly expand its international presence.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, November 29, 2022
Biotechnology, General Health, Medical Devices, Health, Health Technology, 3rd Floor, Trademark dilution, Security (finance), Sale, SEC filing, Risk, Research, SAW, Form, Biofilm, Park Avenue, Clinical trial

The offering is expected to close on or about December 1, 2022, subject to satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about December 1, 2022, subject to satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering for general working capital purposes.
  • The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a shelf registration statement on Form S-3 (File No.
  • The offering is being made only by means of a prospectus supplement that forms a part of the effective registration statement.

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

Retrieved on: 
Monday, November 28, 2022
Biotechnology, General Health, FDA, Medical Devices, Health, Food, Pain, Safety, Trademark dilution, Chronic pain, Patient, Joint, Food and Drug Administration, Security (finance), Sale, Research, Risk, SAW, Biofilm, Clinical trial, FDA, Medical device, Medical imaging

NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield MD PLUS, its dual-actuator ultrasound pain therapy device.

Key Points: 
  • NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield MD PLUS, its dual-actuator ultrasound pain therapy device.
  • Brian Murphy, CEO of NanoVibronix, stated, Securing 510(k) clearance for PainShield Plus is a key milestone towards achieving permanent clearance from the FDA and full-scale commercial marketability.
  • PainShield Plus expands on the effectiveness of its predecessor, our original PainShield M.D., by covering twice the treatment area and broadening the opportunities for application.
  • As a result, we have started the process of making the recommended modifications to the device in order to comply with the FDA standard.

InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

Retrieved on: 
Monday, November 28, 2022
University at Buffalo, Doctor of Philosophy, Stroke, Massachusetts General Hospital, Xi, Hospital, Neurosurgery, University, Intervention, NSPR, Trademark dilution, TEL, FACS, EPS, MD, Security (finance), Infarction, Sale, Radiology, FAHA, Risk, Buffalo, Clinical trial, STEMI, Fireside chats, Dentistry

TEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, 12 Days of Carotid Stenting, which will feature leading multidisciplinary vascular specialists discussing the current and future trends in the carotid treatment market.

Key Points: 
  • TEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, 12 Days of Carotid Stenting, which will feature leading multidisciplinary vascular specialists discussing the current and future trends in the carotid treatment market.
  • The series will be available for viewing beginning on Monday, November 28, 2022.
  • Marvin Slosman, chief executive officer of InspireMD, stated, This truly unique video series featuring some of the most renowned thought leaders in the field of vascular interventions, and we are grateful that they have taken the time to participate in this important initiative.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

ToughBuilt Enters Into Distribution Agreement with One of Kazakhstan’s Largest Equipment Supplier

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Growth, Consumables, Sawhorse, Lamedh, Work-product doctrine, Trademark dilution, Creativity, Government, Security (finance), TBLT, DIY, Risk, Risk management

IRVINE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- ToughBuilt Industries, Inc. ("ToughBuilt") (NASDAQ: TBLT; TBLTW) has announced today that it has entered into a distribution agreement with Lamed LLP (Lamed) one of the largest suppliers of equipment, tools and building materials in Kazakhstan.

Key Points: 
  • IRVINE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- ToughBuilt Industries, Inc. ("ToughBuilt") (NASDAQ: TBLT; TBLTW) has announced today that it has entered into a distribution agreement with Lamed LLP (Lamed) one of the largest suppliers of equipment, tools and building materials in Kazakhstan.
  • Lamed begins this agreement with 76 ToughBuilt SKUs and will stock the entire ToughBuilt product range.
  • Formed in 1991, Lamed has expanded into a high-volume trading company serving both construction professionals, and DIY enthusiasts across the ninth largest nation in the world.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium

Retrieved on: 
Tuesday, November 15, 2022
Xi, Trademark dilution, Security (finance), Sale, Risk, Clinical trial, NSPR, Risk management

InspireMDs common stock is quoted on the Nasdaq under the ticker symbol NSPR.

Key Points: 
  • InspireMDs common stock is quoted on the Nasdaq under the ticker symbol NSPR.
  • We routinely post information that may be important to investors on our website.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.